Dengue fever: epidemiology, clinical manifestations, diagnosis, and therapeutic strategies
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Dengue, a mosquito-borne viral infection, is rapidly increasing worldwide and affects overhalf of the world’s population in at-risk areas. Factors such as globalization, urbanization, andclimate change have fueled its rapid geographical expansion. Although no indigenous denguecases have been identified in Korea, the number of imported dengue cases has increasedfrom travel to endemic regions. In Korea, dengue diagnosis relies mainly on detecting anti-dengue antibodies or viral nucleic acids using real-time polymerase chain reaction. Althoughspecific antiviral treatments for dengue are currently unavailable, promising progress hasbeen made in developing antiviral agents that target viral replication. Single-dose tetravalentlive-attenuated dengue vaccine candidates are currently being evaluated for their safety andefficacy. Innovative vector control methods, including Wolbachia-infected and geneticallymodified species of Aedes mosquitos, have demonstrated promising results. Owing to thelimited therapeutic options, vector control strategies remain a primary focus for preventingtransmission, alongside ongoing research on antiviral drugs and vaccine development. Thisreview provides insight into dengue fever transmission, clinical manifestations, and diagnosis. Additionally, it covers current global control measures, emerging treatment options, and thestatus of vaccines in development.
Abstract
Dengue, a mosquito-borne viral infection, is rapidly increasing worldwide and affects overhalf of the world’s population in at-risk areas. Factors such as globalization, urbanization, andclimate change have fueled its rapid geographical expansion. Although no indigenous denguecases have been identified in Korea, the number of imported dengue cases has increasedfrom travel to endemic regions. In Korea, dengue diagnosis relies mainly on detecting anti-dengue antibodies or viral nucleic acids using real-time polymerase chain reaction. Althoughspecific antiviral treatments for dengue are currently unavailable, promising progress hasbeen made in developing antiviral agents that target viral replication. Single-dose tetravalentlive-attenuated dengue vaccine candidates are currently being evaluated for their safety andefficacy. Innovative vector control methods, including Wolbachia-infected and geneticallymodified species of Aedes mosquitos, have demonstrated promising results. Owing to thelimited therapeutic options, vector control strategies remain a primary focus for preventingtransmission, alongside ongoing research on antiviral drugs and vaccine development. Thisreview provides insight into dengue fever transmission, clinical manifestations, and diagnosis. Additionally, it covers current global control measures, emerging treatment options, and thestatus of vaccines in development.
참고문헌 (68)
- WHO, "Dengue guidelines for diagnosis, treatment, prevention and control: new edition" (2009), World Health Organization
- Kraemer MU, "The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus", eLife, 4, pp.e08347~ (2015)
- Chen LH, "Epidemiology and burden of dengue fever in the United States : a systematic review", J Travel Med, 30, pp.taad127~ (2023)
- Ferreira GL, "Global dengue epidemiology trends", Rev Inst Med Trop Sao Paulo, 54, pp.5~6 (2012)
- Bhatt S, "The global distribution and burden of dengue", Nature, 496, pp.504~507 (2013)
- Gubler DJ, "New treatment strategies for dengue and other flaviviral diseases: Novartis foundation symposium 277", pp.3~22 (2006), John Wiley & Sons
- Gubler DJ, "Dengue, urbanization and globalization : the unholy trinity of the 21st century", Trop Med Health, 39, pp.S3~11 (2011)
- Murray NEA, "Epidemiology of dengue : past, present and future prospects", Clin Epidemiol, pp.299~309 (2013)
- Messina JP, "The current and future global distribution and population at risk of dengue", Nat Microbiol, 4, pp.1508~1515 (2019)
- "Infectious diseases portal"[URL]
- Cho KH, "International travel and exotic dengue fever in South Korea from 2006 to 2015", Jpn J Infect Dis, 71, pp.378~381 (2018)
- Kim JS, "Serotypes of imported dengue fever cases in South Korea, 2018-2020", Public Health Wkly Rep, 14, pp.2366~2373 (2021)
- Chung SM, "Dengue-associated hemophagocytic lymphohistiocytosis in an adult : a case report and literature review", Medicine, 96, pp.e6159~ (2017)
- Park S, "Acute colitis associated with dengue fever in a renal transplant recipient", Transplant Proc, 40, pp.2431~2432 (2008)
- Suh SJ, "A case of imported dengue fever with acute hepatitis", Korean J Hepatol, 13, pp.556~559 (2007)
- Chang CY, "Acute diverticulitis : a rare complication of dengue fever", Chonnam Med J, 57, pp.158~ (2021)
- Mason PW, "Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1", Virol, 161, pp.262~267 (1987)
- Teixeira MdG, "Epidemiologia e medidas de prevenção do dengue", Inf Epidemiol Sus, 8, pp.5~33 (1999)
- Zahoor MK, "Dengue fever: a resilient threat in the face of innovation", pp.1~ (2019), IntechOpen
- Ferreira-de-Lima VH, "Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus : a systematic review", Parasit Vectors, 11, pp.1~8 (2018)
- Kulkarni R, "Risk of transfusion-associated dengue : screening of blood donors from Pune, western India", Transfusion, 59, pp.458~462 (2019)
- Trejo I, "Changing temperature profiles and the risk of dengue outbreaks", PLoS Clim, 2, pp.e0000115~ (2023)
- Guzman MG, "Dengue infection", Nat Rev Dis Primers, 2, pp.16055~ (2016)
- Chouin-Carneiro T, "Biological control of pest and vector insects", pp.2~ (2017), IntechOpen
- Tjaden NB, "Extrinsic incubation period of dengue : knowledge, backlog, and applications of temperature dependence", PLoS Negl Trop Dis, 7, pp.e2207~ (2013)
- Yoon IK, "Fine scale spatiotemporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages", PLoS Negl Trop Dis, 6, pp.e1730~ (2012)
- Li HH, "Mechanical transmission of dengue virus by Aedes aegypti may influence disease transmission dynamics during outbreaks", eBioMedicine, 94, pp.104723~ (2023)
- Gómez M, "Aedes aegypti and Ae. albopictus microbiome", virome: new strategies for controlling arboviral transmission?, 2022, pp.15, 287~
- Kalayanarooj S, "Clinical manifestations and management of dengue", DHF, Trop Med Health, pp.2011, 39[DOI]
- Kala MP, "Dengue: update on clinically relevant therapeutic strategies and vaccines", Curr Treat Options Infect Dis, 15, pp.27~52 (2023)
- Yacoub S, "Cardiovascular manifestations of the emerging dengue pandemic", Nat Rev Cardiol, 11, pp.335~345 (2014)
- Kularatne SA, "Dengue infection : global importance, immunopathology and management", Clin Med, 22, pp.9~13 (2022)
- Tejo AM, "Severe dengue in the intensive care unit", J Intensive Med, 4, pp.16~33 (2024)
- Wilder-Smith A, "Dengue in travelers", N Engl J Med, 353, pp.924~932 (2005)
- Guzman MG, "Multicountry evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis", PLoS Negl Trop Dis, 4, pp.e811~ (2010)
- Macêdo JV, "A systematic review and metaanalysis on the accuracy of rapid immunochromatographic tests for dengue diagnosis", Eur J Clin Microbiol Infect Dis, 41, pp.1191~1201 (2022)
- Clarke DH, "Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses", Am J Trop Med Hyg, 7, pp.561~573 (1958)
- Simmons CP, "Dengue", N Engl J Med, 366, pp.1423~1432 (2012)
- Casenghi M, "NS1 antigen detecting assays for diagnosing acute dengue infection in people living in or returning from endemic countries", Cochrane Database Syst Rev (2014)
- Sang CT, "Evaluation of a commercial capture enzyme-linked immunosorbent assay for detection of immunoglobulin M and G antibodies produced during dengue infection", Clin Diagn Lab Immunol, 5, pp.7~10 (1998)
- Schwartz E, "Evaluation of ELISA-based serodiagnosis of dengue fever in travelers", J Clin Virol, 19, pp.169~173 (2000)
- Park JH, "Dengue fever in South Korea, 2006–2010", Emerg Infect Dis, 18, pp.1525~ (2012)
- Tayal A, "Management of dengue : an updated review", Indian J Pediatr, 90, pp.168~177 (2023)
- Kaptein SJ, "A panserotype dengue virus inhibitor targeting the NS3–NS4B interaction", Nature, 598, pp.504~509 (2021)
- Low ZX, "Antiviral activity of silymarin and baicalein against dengue virus", Sci Rep, 11, pp.21221~ (2021)
- Achee NL, "A critical assessment of vector control for dengue prevention", PLoS Negl Trop Dis, 9, pp.e0003655~ (2015)
- Jing Q, "Dengue epidemiology", Glob J Health Sci, 3, pp.37~45 (2019)
- Ritchie SA, "Advances in vector control science : rear-and-release strategies show promise… but don’t forget the basics", J Infect Dis, 215, pp.S103~8 (2017)
- Fox T, "Wolbachiacarrying Aedes mosquitoes for preventing dengue infection", Cochrane Database Syst Rev (2023)
- Moreira LA, "A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and Plasmodium", Cell, 139, pp.1268~1278 (2009)
- Lambrechts L, "Assessing the epidemiological effect of Wolbachia for dengue control", Lancet Infect Dis, 15, pp.862~866 (2015)
- Zhang H, "Releasing Wolbachia-infected Aedes aegypti to prevent the spread of dengue virus : a mathematical study", Infect Dis Model, 5, pp.142~160 (2020)
- Ross PA, "A decade of stability for wMel Wolbachia in natural Aedes aegypti populations", PLoS Pathog, 18, pp.e1010256~ (2022)
- Hoffmann AA, "Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission", Nature, 476, pp.454~457 (2011)
- Walker T, "The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations", Nature, 476, pp.450~453 (2011)
- Ritchie S, "Rear and release : a new paradigm for dengue control", Austral Entomol, 53, pp.363~367 (2014)
- Lenharo M, "Dengue is spreading. Can new vaccines and antivirals halt its rise?", Nature, 623, pp.470~ (2023)
- Hadinegoro SR, "Efficacy and long-term safety of a dengue vaccine in regions of endemic disease", N Engl J Med, 373, pp.1195~1206 (2015)
- Wilder-Smith A, "Deliberations of the Strategic Advisory Group of Experts on immunization on the use of CYD-TDV dengue vaccine", Lancet Infect Dis, 19, pp.e31~8 (2019)
- López-Medina E, "Efficacy of a dengue vaccine candidate(TAK-003)in healthy children and adolescents 2years after vaccination", J Infect Dis, 225, pp.1521~1532 (2022)
- Malavige GN, "Facing the escalating burden of dengue : challenges and perspectives", PLoS Glob Public Health, 3, pp.e0002598~ (2023)
- Kallás EG, "Live, attenuated, tetravalent Butantan–Dengue vaccine in children and adults", N Engl J Med, 390, pp.397~408 (2024)
- Gunale B, "A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults", Vaccine, 41, pp.5614~5621 (2023)
- Wilder-Smith A, "Dengue vaccine development : challenges and prospects", Curr Opin Infect Dis, 35, pp.390~396 (2022)
- Thisyakorn U, "Latest developments and future directions in dengue vaccines", Ther Adv Vaccines Immunother, 2, pp.3~9 (2014)
- Young E, "A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotypespecific immunity", Nat Commun, 14, pp.1371~ (2023)
- Sakinah S, "Stem cell therapy in dengue virus-infected BALB", C mice improves hepatic injury, 2021, pp.9, 637270~
- Rodriguez-Manzano J, "Improving dengue diagnostics and management through innovative technology", Curr Infect Dis Rep, 20, pp.1~8 (2018)